Adaptive Biotechnologies (ADPT) Return on Capital Employed (2019 - 2026)

Adaptive Biotechnologies has disclosed Return on Capital Employed across 8 years of filings, most recently posting 11.06% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 11.06%, up 2173.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 11.06% (up 2173.0% YoY), and the FY2025 annual result was 13.1%, up 1927.0% from the prior year.
• Return on Capital Employed came in at 11.06% for Q1 2026 at Adaptive Biotechnologies, up from 13.87% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 11.06% in Q1 2026 to a low of 42.39% in Q2 2024.
• The 5-year median for Return on Capital Employed is 30.02% (2022), against an average of 29.75%.
• Across the five-year window, Return on Capital Employed tumbled 1462 bps in 2024 and jumped 2221 bps in 2025, its largest moves.
• Adaptive Biotechnologies' Return on Capital Employed stood at 26.32% in 2022, then sank by 43 bps to 37.75% in 2023, then climbed by 5 bps to 36.05% in 2024, then jumped by 62 bps to 13.87% in 2025, then gained by 20 bps to 11.06% in 2026.
• The last three Return on Capital Employed figures came in at 11.06% (Q1 2026), 13.87% (Q4 2025), and 19.06% (Q3 2025), per Business Quant data.